Live Analyst Rating Changes 23828 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Yun Zhong
WEDB

Yun Zhong

Wedbush
Wall Street Analyst
★★★☆☆
#2126
on 13Foresight · ranked by our own returns
43%
Success Rate
+11.8%
Average Return
25 of 58 calls profitable · +4.3% vs benchmark
S&P 500 (SPY)
🔒 5-year track record is Pro. Showing 1-year — upgrade.
📈 Across the calls we could measure, roughly 43% of Yun Zhong's ratings turned a profit when each position was held for 1 year — averaging +11.8% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

157 Buy 10 Hold 0 Sell
Yun's Stock Coverage 29 ratings · 2026-08-13
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
RCKT
Rocket Pharmaceuticals
 Aug 11, 2026 BUY Buy
+384.4% avg upside
29 analysts
$15.00
336.59% Upside
 · ·
SGMT
Sagimet Biosciences, Inc. Class A
 Aug 11, 2026 BUY Strong Buy
+198.9% avg upside
15 analysts
$28.00
192.32% Upside
 -2.6% ·
PTGX
Protagonist Therapeutics
 Aug 10, 2026 BUY Strong Buy
-23.0% avg upside
19 analysts
$173.00
16.63% Upside
 +1.6% ·
MLTX
MoonLake Immunotherapeutics
 Aug 10, 2026 BUY Strong Buy
+70.0% avg upside
20 analysts
$34.00
108.50% Upside
 -0.6% ·
VYGR
Voyager Therapeutics
 Aug 07, 2026 BUY Strong Buy
+346.7% avg upside
23 analysts
$8.00
150.43% Upside
 +0.0% ·
BMRN
BioMarin Pharmaceutical
 Aug 07, 2026 BUY Strong Buy
+35.2% avg upside
52 analysts
$94.00
35.55% Upside
 +8.4% ·
IRD
Opus Genetics
 Aug 06, 2026 BUY Strong Buy
+174.6% avg upside
25 analysts
$10.00
159.67% Upside
 -1.6% ·
SRPT
Sarepta Therapeutics
 Aug 06, 2026 BUY Buy
+225.4% avg upside
49 analysts
$35.00
96.67% Upside
 +0.0% ·
ASND
Ascendis Pharma
 Aug 06, 2026 BUY Strong Buy
+8.1% avg upside
24 analysts
$327.00
28.73% Upside
 -0.7% ·
MNKD
MannKind
 Aug 06, 2026 BUY Buy
+82.4% avg upside
22 analysts
$8.00
107.74% Upside
 -1.0% ·
KROS
Keros Therapeutics
 Aug 04, 2026 HOLD Strong Buy
+119.7% avg upside
21 analysts
$16.00
51.29% Upside
 +9.3% ·
WVE
Wave Life Sciences
 Jul 31, 2026 BUY Strong Buy
+299.0% avg upside
28 analysts
$12.00
132.18% Upside
 -4.2% ·
BNTC
Benitec Biopharma
 Jul 28, 2026 BUY Strong Buy
+96.5% avg upside
14 analysts
$16.00
19.22% Upside
 +7.4% ·
CAMP
CAMP4 Therapeutics Corporation
 Jul 27, 2026 BUY Strong Buy
+114.8% avg upside
9 analysts
$8.00
86.94% Upside
 +31.6% ·
KLRS
Kalaris Therapeutics
 Jul 17, 2026 BUY Buy
+220.0% avg upside
13 analysts
$17.00
312.59% Upside
 -9.1% ·
RZLT
Rezolute
 Jun 03, 2026 BUY Strong Buy
+126.0% avg upside
13 analysts
$6.00
27.67% Upside
 +2.2% ·
PASG
Passage Bio
 Apr 21, 2026 HOLD Buy
+281.5% avg upside
14 analysts
$8.00
77.09% Upside
 -25.2% ·
TSHA
Taysha Gene Therapies
 Mar 30, 2023 HOLD Strong Buy
+116.5% avg upside
21 analysts
 — +298.6% ·
AVXL
Anavex Life Sciences
 Mar 30, 2023 BUY Strong Buy
+595.6% avg upside
9 analysts
$28.00
709.18% Upside
 -38.8% ·
QURE
uniQure
 Mar 28, 2023 BUY Strong Buy
+31.0% avg upside
29 analysts
$38.00
14.98% Downside
 -74.1% ·
TECX
Tectonic Therapeutic
 Mar 23, 2023 BUY Strong Buy
+59.4% avg upside
24 analysts
$4.00
87.53% Downside
 +43.8% ·
RNAC
Cartesian Therapeutics
 Mar 21, 2023 BUY Strong Buy
+265.0% avg upside
19 analysts
$8.00
6.71% Downside
 -44.1% ·
MREO
Mereo Biopharma Group Plc
 Mar 21, 2023 BUY Strong Buy
+1218.3% avg upside
11 analysts
$4.00
1209.31% Upside
 +240.2% ·
LENZ
LENZ Therapeutics
 Mar 21, 2023 HOLD Buy
+306.3% avg upside
17 analysts
 — +93.9% ·
DNTH
Dianthus Therapeutics
 Jan 26, 2023 HOLD Strong Buy
-11.9% avg upside
29 analysts
 — +154.0% ·
MRKR
Marker Therapeutics
 May 12, 2020 BUY Strong Buy
+1165.8% avg upside
9 analysts
$10.00
813.15% Upside
 -8.5% ·
ELOX
Eloxx Pharmaceuticals
 Feb 04, 2020 BUY Strong Buy
+97.4% avg upside
10 analysts
$14.00
26.82% Downside
 · ·
DNLI
Denali Therapeutics
 Nov 12, 2018 BUY Strong Buy
+52.6% avg upside
24 analysts
 — -9.9% ·
SMMT
Summit Therapeutics
 Jun 28, 2018 HOLD Strong Buy
+88.9% avg upside
27 analysts
 — -47.1% ·
🔒 24 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Yun Zhong — Frequently Asked Questions
How accurate are Yun Zhong's stock ratings?
Based on the calls 13Foresight could measure, about 45% of Yun's ratings were profitable over a one-year hold, with an average return of +12.0% per rating, or +4.5% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Yun ranked on 13Foresight?
Yun Zhong is currently ranked #2126 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Yun cover?
Yun most recently has ratings on RCKT, SGMT, PTGX, MLTX, VYGR, BMRN, IRD, SRPT, ASND, MNKD, KROS, WVE and 17 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.